| ORTHOCLONE_OKT3 |
Muromonab-CD3 |
CD3 |
Transplants |
1985 |
| CEA-SCAN |
Arcitumomab |
CD66 (CEA) |
Cancer |
1996 |
| MYLOTARG |
Gemtuzumab-ozogamicin |
CD33 |
Cancer |
1996 |
| PROSTASCINT |
Capromabpendetide |
PSMA |
Cancer |
1996 |
| VERLUMA |
Nofetumomab-merpentan |
Glycoprotein (EpCAM;CD20) |
Cancer |
1996 |
| REOPRO |
Abciximab |
CD41 (Integrin alpha-IIb) |
|
1997 |
| RITUXAN |
Rituximab |
CD20 |
Autoimmunity; Cancer |
1997 |
| ZENPAX |
Daclizumab |
CD25 (α chain of IL-2R) |
Transplants |
1997 |
| ENBREL |
Etanercept |
TNFα |
Autoimmunity |
1998 |
| HERCEPTIN |
Trastuzumab |
CD340 (HER2) |
Cancer |
1998 |
| REMICADE |
Infliximab |
TNFα |
Autoimmunity |
1998 |
| SIMULECT |
Basiliximab |
CD25 (α chain of IL-2R) |
Transplants |
1998 |
| SYNAGIS |
Palivizumab |
F protein of RSV |
Viral Infection |
1998 |
| LEMTRADA |
Alemtuzumab |
CD52 |
Cancer |
2001 |
| CAMPATH |
Alemtuzumab |
CD52 |
Autoimmunity |
2001 |
| HUMIRA |
Adalimumab |
TNFα |
Autoimmunity |
2002 |
| ZEVALIN |
Ibritumomab-tiuxetan |
CD20 |
Cancer |
2002 |
| AMEVIVE |
Alefacept |
CD2 |
Autoimmunity |
2003 |
| BEXXAR |
Tositumomab |
CD20 |
Cancer |
2003 |
| RAPTIVA |
Efalizumab |
CD11a (LFA-1) |
Autoimmunity |
2003 |
| XOLAIR |
Omalizumab |
IgE Fc region |
Autoimmunity |
2003 |
| AVASTIN |
Bevacizumab |
VEGF-A |
Cancer |
2004 |
| ERBITUX |
Cetuximab |
EGFR |
Cancer |
2004 |
| TYSABRI |
Natalizumab |
integrin α4 |
Autoimmunity |
2004 |
| ORENCIA |
Abatacept |
CD80; CD86 |
Autoimmunity |
2005 |
| LUCENTIS |
Ranibizumabd |
VEGF-A |
|
2006 |
| VECTIBIX |
Panitumumab |
EGFR |
Cancer |
2006 |
| SOLIRIS |
Eculizumab |
C5 |
|
2007 |
| ARCALYST |
Rilonacept |
IL-1 |
|
2008 |
| CIMZIA |
Certolizumab-pegol |
TNFα |
Autoimmunity |
2008 |
| NPLATE |
Romiplostim |
CD110 (Thrombopoietin receptor) |
|
2008 |
| ARZERRA |
Ofatumumab |
CD20 |
Cancer |
2009 |
| ILARIS |
Canakinumab |
IL-1b |
|
2009 |
| REMOVAB |
Catumaxomab |
EpCAM |
Cancer |
2009 EMA |
| SIMPONI |
Golimumab |
TNFα |
Autoimmunity |
2009 |
| SIMPONI_ARIA |
Golimumab |
TNFα |
Autoimmunity |
2009 |
| STELARA |
Ustekinumab |
IL-12; IL-23 |
Autoimmunity |
2009 |
| ACTEMRA |
Tocilizumab |
CD126 (IL-6R) |
Autoimmunity |
2010 |
| PROLIA |
Denosumab |
CD254 (RANKL) |
|
2010 |
| XGEVA |
Denosumab |
CD254 (RANKL) |
Cancer |
2010 |
| ADCETRIS |
Brentuximab-vedotin |
CD30 (TNFRSF8) |
Cancer |
2011 |
| BENLYSTA |
Belimumab |
CD257 (BAFF) |
Autoimmunity |
2011 |
| NULOJIX |
Belatacept |
CD80; CD86 |
Transplants |
2011 |
| YERVOY |
Ipilimumab |
CD152 (CTLA-4) |
Cancer |
2011 |
| PERJETA |
Pertuzumab |
CD340 (HER2) |
Cancer |
2012 |
| RAXIBACUMAB |
Raxibacumab |
anthrax toxin; protective antigen |
Fungal Infection |
2012 |
| GAZYVA |
Obinutuzumab |
CD20 |
Cancer |
2013 |
| KADCYLA |
Ado-Trastuzumab-emtansine |
CD340 (HER2) |
Cancer |
2013 |
| BLINCYTO |
Blinatumomab |
CD19 |
Cancer |
2014 |
| CYRAMZA |
Ramucirumab |
VEGFR2 |
Cancer |
2014 |
| ENTYVIO |
Vedolizumab |
Integrin α4β7 |
Autoimmunity |
2014 |
| KEYTRUDA |
Pembrolizumab |
CD279 (PD-1) |
Cancer |
2014 |
| OPDIVO |
Nivolumab |
CD279 (PD-1) |
Cancer |
2014 |
| SYLVANT |
Siltuximab |
IL-6 |
|
2014 |
| COSENTYX |
Secukinumab |
IL-17α |
Autoimmunity |
2015 |
| DARZALEX |
Daratumumab |
CD38 |
Cancer |
2015 |
| EMPLICITI |
Elotuzumab |
CD319 (SLAMF7) |
Cancer |
2015 |
| NUCALA |
Mepolizumab |
IL-5 |
Autoimmunity |
2015 |
| PORTRAZZA |
Necitumumab |
EGFR |
Cancer |
2015 |
| PRALUENT |
Alirocumab |
PCSK9 |
|
2015 |
| PRAXBIND |
Idarucizumab |
Dabigatran |
|
2015 |
| REPATHA |
Evolocumab |
PCSK9 |
|
2015 |
| UNITUXIN |
Dinutuximab |
GD2 ganglioside |
Cancer |
2015 |
| ZINBRYTA |
Daclizumab |
CD25 (α chain of IL-2R) |
Autoimmunity |
2016 |
| AMJEVITA |
Adalimumab-Atto |
TNFα |
Autoimmunity |
2016 |
| ANTHIM |
Obiltoxaximab |
Bacillus anthracis anthrax |
Bacterial Infection |
2016 |
| CINQUAIR |
Reslizumab |
IL-5 |
Autoimmunity |
2016 |
| INFLECTRA |
Infliximab-dyyb |
TNFα |
Autoimmunity |
2016 |
| LARTRUVO |
Olaratumab |
PDGF-Rα |
Cancer |
2016 |
| TALTZ |
Ixekizumab |
IL-17α |
Autoimmunity |
2016 |
| TECENTRIQ |
Atezolizumab |
CD274 (PD-L1) |
Cancer |
2016 |
| ZINPLAVA |
Bezlotoxumab |
Clostridium difficile Toxin B |
Bacterial Infection |
2016 |
| BAVENCIO |
Avelumab |
CD274 (PD-L1) |
Cancer |
2017 |
| DUPIXENT |
Dupliumab |
IL-4Rα |
Autoimmunity |
2017 |
| OCREVUS |
Ocrelizumab |
CD20 |
Autoimmunity |
2017 |
| SILIQ |
Brodalumab |
IL-17R |
Autoimmunity |
2017 |
| MVASI |
bevacizumab-awwb |
VEGF-A |
Cancer |
2017 |
| BESPONSA |
Inotuzumab-ozogamicin |
CD22 |
Cancer |
2017 |
| CYLTEZO |
Adalimumab-Adbm |
TNFα |
Autoimmunity |
2017 |
| IMFINZI |
Durvalumab |
CD274 (PD-L1) |
Cancer |
2017 |
| KEVZARA |
Sarilumab |
CD126 (IL-6R) |
Autoimmunity |
2017 |
| RENFLEXIS |
Infliximab-abda |
TNFα |
Autoimmunity |
2017 |
| RITUXAN_HYCELA |
Rituximab-hyaluronidase |
CD20 |
Cancer |
2017 |
| TREMFYA |
Guselkumab |
IL-23α |
Autoimmunity |
2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|